Literature DB >> 21286666

Lentiviral-mediated siRNA targeted against osteopontin suppresses the growth and metastasis of gastric cancer cells.

Zhi-Ming Wang1, Yue-Hong Cui, Wei Li, Shi-Yao Chen, Tian-Shu Liu.   

Abstract

The expression of osteopontin (OPN) has been correlated with tumor growth and metastasis. However, the mechanisms by which OPN promotes tumor metastasis remain unclear. In this study, we aimed to investigate the anti-tumor effects of OPN by silencing OPN expression in the gastric cancer cell line SGC7901, using lentiviral-OPN small interfering RNA (siRNA) technology. Plasmid vectors containing OPN siRNAs were generated, encoded with lentiviral vector and transfected into SGC7901 cells (SGC-OPN- cells). OPN mRNA and protein expression were examined using real-time reverse transcription polymerase chain reaction (RT-PCR) and Western blotting techniques. The tumorigenicity and metastatic potential of SGC7901 cells were studied in nude mice. Expression of OPN and vascular endothelial growth factor (VEGF) in lung metastatic tumor specimens were also examined using immunohistochemistry (IHC). Among the three siRNA sequences tested, siRNA2 most remarkably inhibited mRNA levels of OPN; lentiviral-siRNA2 was stably transfected into SGC7901 cells to generate SGC-OPN- cells. SGC-OPN- cells had significantly decreased OPN expression compared to control cells (relative intensities were 0.14 ± 0.06 vs. 0.95 ± 0.16 in controls, P<0.01). A substantial reduction in detectable tumors was found in mice implanted with SGC-OPN- cells compared to controls (4.62 ± 1.24 vs. 8.35 ± 2.27 cm3 in controls, P<0.01). In addition, mice implanted with SGC-OPN- cells survived longer (101.2 ± 22.5 vs. 89.2 ± 24.6 d, P<0.01) and were demonstrated to have less metastases compared to mice implanted with SGC7901 control cells. Interestingly, lentiviral-siRNA2 also suppressed the expression of OPN and VEGF in metastatic lung specimens. Lentiviral-mediated OPN siRNA significantly reduced OPN gene expression, suppressing the growth and metastasis of gastric cancers, which might be related to reduced expression of VEGF. Therefore, OPN could serve as a promising therapeutic target for gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21286666     DOI: 10.3892/or.2011.1168

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer.

Authors:  Maria Di Bartolomeo; Filippo Pietrantonio; Alessandro Pellegrinelli; Antonia Martinetti; Luigi Mariani; Maria Grazia Daidone; Emilio Bajetta; Giuseppe Pelosi; Filippo de Braud; Irene Floriani; Rosalba Miceli
Journal:  Gastric Cancer       Date:  2015-04-11       Impact factor: 7.370

Review 2.  Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.

Authors:  Dong-Xing Cao; Zhi-Jie Li; Xiao-Ou Jiang; Yick Liang Lum; Ester Khin; Nikki P Lee; Guo-Hao Wu; John M Luk
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

3.  Osteopontin expression in co-cultures of human squamous cell carcinoma-derived cells and osteoblastic cells and its effects on the neoplastic cell phenotype and osteoclastic activation.

Authors:  Lucas Novaes Teixeira; Larissa Moreira Spinola de Castro Raucci; Gabriela Caroline Alonso; Ricardo Della Coletta; Adalberto Luiz Rosa; Paulo Tambasco de Oliveira
Journal:  Tumour Biol       Date:  2016-06-16

4.  The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression.

Authors:  Chang-Ni Lin; Chih-Jung Wang; Ying-Jui Chao; Ming-Derg Lai; Yan-Shen Shan
Journal:  BMC Cancer       Date:  2015-03-15       Impact factor: 4.430

Review 5.  The role of osteopontin in the progression of solid organ tumour.

Authors:  Hailin Zhao; Qian Chen; Azeem Alam; Jiang Cui; Ka Chun Suen; Aurelie Pac Soo; Shiori Eguchi; Jianteng Gu; Daqing Ma
Journal:  Cell Death Dis       Date:  2018-03-02       Impact factor: 8.469

6.  ISL1 predicts poor outcomes for patients with gastric cancer and drives tumor progression through binding to the ZEB1 promoter together with SETD7.

Authors:  Ting Guo; Xian-Zi Wen; Zi-Yu Li; Hai-Bo Han; Chen-Guang Zhang; Yan-Hua Bai; Xiao-Fang Xing; Xiao-Jing Cheng; Hong Du; Ying Hu; Xiao-Hong Wang; Yong-Ning Jia; Meng-Lin Nie; Meng Xie; Qing-Da Li; Jia-Fu Ji
Journal:  Cell Death Dis       Date:  2019-01-15       Impact factor: 8.469

7.  Insulin gene enhancer protein 1 mediates glycolysis and tumorigenesis of gastric cancer through regulating glucose transporter 4.

Authors:  Ting Guo; Yan-Hua Bai; Xiao-Jing Cheng; Hai-Bo Han; Hong Du; Ying Hu; Shu-Qin Jia; Xiao-Fang Xing; Jia-Fu Ji
Journal:  Cancer Commun (Lond)       Date:  2021-02-11

8.  Promotive effect of Talin-1 protein on gastric cancer progression through PTK2-PXN-VCL-E-Cadherin-CAPN2-MAPK1 signaling axis.

Authors:  Hongzhu Yan; Min Guo; Jue Zou; Feng Xiao; Lina Yi; Ying He; Bosheng He
Journal:  J Clin Lab Anal       Date:  2020-09-20       Impact factor: 3.124

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.